Age Related Macular Degeneration Amd Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Age Related Macular Degeneration (AMD) market, covering the market size, growth forecasts, industry trends, and regional insights for the period 2023-2033.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.00 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $16.35 Billion |
| Top Companies | Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, Alcon Inc. |
| Last Modified Date | 15 November 2024 |
Age Related Macular Degeneration Amd Market Overview
What is the Market Size & CAGR of Age Related Macular Degeneration Amd market in 2023?
Age Related Macular Degeneration Amd Industry Analysis
Age Related Macular Degeneration Amd Market Segmentation and Scope
Request a custom research report for industry.
Age Related Macular Degeneration Amd Market Analysis Report by Region
Europe Age Related Macular Degeneration Amd Market Report:
Europe is projected to grow from a market size of $2.37 billion in 2023 to $4.84 billion by 2033. The growth is attributed to an aging population, high disposable incomes, and increased focus on eye health.Asia Pacific Age Related Macular Degeneration Amd Market Report:
The Asia Pacific region had a market valuation of $1.47 billion in 2023, projected to grow to $3.00 billion by 2033. Factors driving growth include increased healthcare expenditure, rising awareness of eye health issues, and a significant geriatric population.North America Age Related Macular Degeneration Amd Market Report:
North America holds a significant market share, valued at $2.99 billion in 2023, forecasted to grow to $6.11 billion by 2033. This growth is driven by advanced healthcare infrastructure, high awareness levels, and substantial R&D investments.South America Age Related Macular Degeneration Amd Market Report:
In South America, the AMD market was valued at $0.28 billion in 2023 and expected to reach $0.57 billion by 2033. Growth factors include increasing healthcare access and improving economic conditions which enhance overall patient care.Middle East & Africa Age Related Macular Degeneration Amd Market Report:
The market in the Middle East and Africa stood at $0.90 billion in 2023 and is expected to grow to $1.83 billion by 2033, driven by improving healthcare services and rising awareness of health conditions.Request a custom research report for industry.
Age Related Macular Degeneration Amd Market Analysis By Disease Type
Global Age-Related Macular Degeneration (AMD) Market, By Disease Type Market Analysis (2024 - 2033)
The AMD market segmentation by disease type highlights Dry AMD commanding a significant market share with a size of $6.54 billion in 2023, expected to grow to $13.37 billion by 2033, holding steady at 81.78% market share. Wet AMD, while smaller, is projected to grow from $1.46 billion to $2.98 billion, maintaining an 18.22% share.
Age Related Macular Degeneration Amd Market Analysis By Treatment Type
Global Age-Related Macular Degeneration (AMD) Market, By Treatment Type Market Analysis (2024 - 2033)
Pharmaceuticals represent the largest share in treatment types, valued at $5.36 billion in 2023, expected to reach $10.95 billion by 2033 with a 66.97% market share. Surgical procedures and nutritional supplements are also crucial, with sizes expected to grow from $1.67 billion to $3.41 billion and $0.98 billion to $2.00 billion, respectively.
Age Related Macular Degeneration Amd Market Analysis By Distribution Channel
Global Age-Related Macular Degeneration (AMD) Market, By Distribution Channel Market Analysis (2024 - 2033)
The distribution channel segment indicates that Hospital Pharmacies hold a significant market share of $5.36 billion in 2023 and is projected to double to $10.95 billion by 2033. Retail and online pharmacies follow, with estimated values growing considerably within the same period.
Age Related Macular Degeneration Amd Market Analysis By Stage Of Disease
Global Age-Related Macular Degeneration (AMD) Market, By Stage of Disease Market Analysis (2024 - 2033)
The segmentation by disease stage reveals that the Early Stage holds a substantial market size of $5.36 billion in 2023, anticipated to grow to $10.95 billion. The Intermediate and Advanced Stages are also growing segments, driven by the increasing prevalence of AMD.
Age Related Macular Degeneration Amd Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Age Related Macular Degeneration Amd Industry
Regeneron Pharmaceuticals, Inc.:
A leading player in the AMD market known for its innovative treatments and high-quality research, particularly in developing drug therapies for Wet AMD.Novartis AG:
A global healthcare leader that offers a range of treatments for AMD and is heavily involved in research, focused on improving patient outcomes through innovative therapies.Roche Holdings AG:
Notable for its significant contributions towards advancing AMD treatment solutions, Roche emphasizes precision medicine in its offerings.Bayer AG:
Bayer is recognized for its extensive range of products related to eye diseases, especially for its commitment to research and development in AMD treatments.Alcon Inc.:
A global leader in eye care, Alcon provides a range of surgical and pharmaceutical products targeting AMD, committed to enhancing patient care.We're grateful to work with incredible clients.
Related Industries
FAQs
What is the market size of age Related macular degeneration (AMD)?
The global market size for age-related macular degeneration (AMD) was valued at approximately $8 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.2%, expanding significantly over the next decade.
What are the key market players or companies in the age Related macular degeneration (AMD) industry?
Key players in the AMD market include leading pharmaceutical companies, innovative biotech firms, and specialized retinal clinics. These players are pivotal in advancing treatment options and driving market growth through collaborations and clinical trials.
What are the primary factors driving the growth in the age Related macular degeneration (AMD) industry?
The growth of the AMD industry is driven by factors such as an aging population, increasing prevalence of obesity and diabetes, advancements in treatment options, and rising awareness and diagnostic technologies among healthcare professionals.
Which region is the fastest Growing in the age Related macular degeneration (AMD) market?
North America is currently the fastest-growing region in the AMD market, projected to expand from $2.99 billion in 2023 to $6.11 billion by 2033, driven by increased healthcare investments and innovation in treatment.
Does ConsaInsights provide customized market report data for the age Related macular degeneration (AMD) industry?
Yes, ConsaInsights offers customized market report data tailored to specific needs within the age-related macular degeneration (AMD) industry, allowing clients to gain personalized insights and actionable recommendations.
What deliverables can I expect from this age Related macular degeneration (AMD) market research project?
Deliverables from the AMD market research project typically include comprehensive market analysis reports, segment performance data, competitive landscape assessments, and strategic recommendations for stakeholders.
What are the market trends of age Related macular degeneration (AMD)?
Current trends in the AMD market include a shift towards personalized medicine, increased investment in research & development, the rise of minimally invasive surgical options, and a growing preference for nutritional supplements as adjunct therapies.
What are the market segments for age Related macular degeneration (AMD)?
The AMD market is segmented primarily into Dry and Wet AMD types, with Dry AMD accounting for a majority market share of 81.78% and Wet AMD at 18.22%. Key segments also include Pharmaceuticals, Surgical Procedures, and Nutritional Supplements.